New pain combo could cut opioid use after cancer surgery

NCT ID NCT07263165

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding dexmedetomidine to the standard numbing drug bupivacaine in a specific nerve block can reduce opioid painkiller use and pain intensity after upper abdominal cancer surgery. About 54 adults aged 18-70 scheduled for surgeries like gastrectomy or hepatectomy will be randomly assigned to receive either the combination or bupivacaine alone. The main goal is to see if the combo lowers total opioid consumption in the first 24 hours after surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

dexmedetomidine added to bupivacaine

What this could lead to

If it works, this could offer better pain control and less reliance on opioids after upper abdominal cancer surgery.

What could go wrong

This is a small, early-phase trial with only 54 participants, so results may not apply broadly. The added drug could also cause side effects like low blood pressure or slow heart rate.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OPIOID CONSUMPTION, POSTOPERATIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••